Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

Dynamic contrast-enhanced magnetic resonance imaging-derived kep as a potential biomarker of matrix metalloproteinase 9 expression in patients with glioblastoma multiforme: a pilot study.

Awasthi R, Pandey CM, Sahoo P, Behari S, Kumar V, Kumar S, Misra S, Husain N, Soni P, Rathore RK, Gupta RK.

J Comput Assist Tomogr. 2012 Jan-Feb;36(1):125-30. doi: 10.1097/RCT.0b013e31823f6c59.

PMID:
22261782
2.

Discriminant analysis to classify glioma grading using dynamic contrast-enhanced MRI and immunohistochemical markers.

Awasthi R, Rathore RK, Soni P, Sahoo P, Awasthi A, Husain N, Behari S, Singh RK, Pandey CM, Gupta RK.

Neuroradiology. 2012 Mar;54(3):205-13. doi: 10.1007/s00234-011-0874-y. Epub 2011 May 4.

PMID:
21541688
3.

T1-weighted dynamic contrast-enhanced MR evaluation of different stages of neurocysticercosis and its relationship with serum MMP-9 expression.

Gupta RK, Awasthi R, Garg RK, Kumar N, Gupta PK, Singh AK, Sahoo P, Paliwal VK, Prasad KN, Pandey CM, Rathore RK.

AJNR Am J Neuroradiol. 2013 May;34(5):997-1003. doi: 10.3174/ajnr.A3346. Epub 2012 Nov 22.

4.

Dynamic contrast-enhanced (DCE) derived transfer coefficient (ktrans) is a surrogate marker of matrix metalloproteinase 9 (MMP-9) expression in brain tuberculomas.

Haris M, Husain N, Singh A, Awasthi R, Singh Rathore RK, Husain M, Gupta RK.

J Magn Reson Imaging. 2008 Sep;28(3):588-97. doi: 10.1002/jmri.21491.

PMID:
18777539
5.

Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.

Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2002 Sep;8(9):2894-901.

6.

[Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].

Wei QY, Wu YQ, Fan SQ.

Hunan Yi Ke Da Xue Xue Bao. 2003 Jun;28(3):212-6. Chinese.

PMID:
14653069
7.

Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume.

Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, Chang S, Dillon WP, Nelson SJ.

J Magn Reson Imaging. 2004 May;19(5):546-54.

PMID:
15112303
8.
9.

TLR9 expression is associated with prognosis in patients with glioblastoma multiforme.

Leng L, Jiang T, Zhang Y.

J Clin Neurosci. 2012 Jan;19(1):75-80. doi: 10.1016/j.jocn.2011.03.037. Epub 2011 Dec 9.

PMID:
22169598
10.
11.
12.

Magnetic resonance image-guided proteomics of human glioblastoma multiforme.

Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD.

J Magn Reson Imaging. 2003 Nov;18(5):530-6.

PMID:
14579395
13.

Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme.

Yan W, Zhang W, Sun L, Liu Y, You G, Wang Y, Kang C, You Y, Jiang T.

Brain Res. 2011 Sep 9;1411:108-15. doi: 10.1016/j.brainres.2011.07.002. Epub 2011 Jul 13.

PMID:
21831363
14.

Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas.

Stojic J, Hagemann C, Haas S, Herbold C, Kühnel S, Gerngras S, Roggendorf W, Roosen K, Vince GH.

Neurosci Res. 2008 Jan;60(1):40-9. Epub 2007 Sep 29.

PMID:
17980449
15.

Comparative evaluation of dynamic contrast-enhanced perfusion with diffusion tensor imaging metrics in assessment of corticospinal tract infiltration in malignant glioma.

Awasthi R, Verma SK, Haris M, Singh A, Behari S, Jaiswal AK, Rajput D, Pandey R, Rathore RK, Pandey CM, Gupta RK.

J Comput Assist Tomogr. 2010 Jan;34(1):82-8. doi: 10.1097/RCT.0b013e3181ae29f0.

PMID:
20118727
16.

Relationship between magnetic resonance imaging and molecular pathology in patients with glioblastoma multiforme.

Li WB, Tang K, Zhang W, Yan W, You G, Li SW, Zhang L, Huang YJ, Jiang T.

Chin Med J (Engl). 2011 Sep;124(17):2589-92.

PMID:
22040408
17.

Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9.

Sienel W, Polzer B, Elshawi K, Lindner M, Morresi-Hauf A, Vay C, Eder F, Passlick B, Klein CA.

Mod Pathol. 2008 Sep;21(9):1130-8. doi: 10.1038/modpathol.2008.102. Epub 2008 Jun 20.

18.
19.

Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas.

Law M, Oh S, Johnson G, Babb JS, Zagzag D, Golfinos J, Kelly PJ.

Neurosurgery. 2006 Jun;58(6):1099-107; discussion 1099-107.

PMID:
16723889
20.

Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma.

Ulmer S, Liess C, Kesari S, Otto N, Straube T, Jansen O.

J Neurooncol. 2009 Jan;91(2):213-20. doi: 10.1007/s11060-008-9701-7. Epub 2008 Sep 21.

PMID:
18807224

Supplemental Content

Support Center